AC
AI Cancer Cure
Evidence Atlas, updating nightly
Trials
Research
Support
Alternatives
Cancers
Biomarkers
Updates
Roadmap
Explore
← Back to trials
Trial not found
Could not find
NCT06043323
in the database yet.
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma | AI Cancer Cure